Citi lowered the firm’s price target on Biomea Fusion (BMEA) to $9 from $22 and keeps a Buy rating on the shares. The firm cites the company’s strategic realignment for the target cut. With the focus now metabolic disease, Biomea is no longer pursuing oncology, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion’s Phase 2 Trial: A New Hope for Type 1 Diabetes Treatment
- Biomea Fusion’s BMF-219 Study: A Potential Game-Changer for Type 2 Diabetes
- Biomea Fusion’s BMF-219 Study Update: Implications for Investors
- Largest borrow rate increases among liquid names
- Biomea Fusion price target lowered to $4 from $18 at H.C. Wainwright